Physician profile
Salih Colakoglu
NPI 1043509748
$4,480.47
in general payments reported to CMS, 2019-2025
11 companies · $1,755 in 2025
The $1,755 reported for 2025 was more than what 81% of Plastic and Reconstructive Surgery providers received nationally (typical 2025 total: $445).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2021: $319 · 2022: $222 · 2023: $1,572 · 2024: $487 · 2025: $1,755.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,079 · Travel and Lodging: $735.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,079.04 |
| Travel and Lodging | $735.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tela Bio, INC. | $1,529.83 | 2023-2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex), Ovitex 2s |
| Davol INC. | $1,028.73 | 2023-2025 | Phasix Mesh, Surgiphor |
| Abbvie INC. | $481.70 | 2023-2025 | Natrelle Saline-Filled Breast Implants |
| Allergan, INC. | $267.57 | 2019-2022 | |
| Aroa Biosurgery Incorporated | $206.61 | 2023 | |
| Axogen | $204.67 | 2022-2025 | |
| Kerecis Limited | $203.23 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Integra Lifesciences Corporation | $201.03 | 2021 | |
| Becton, Dickinson and Company | $199.68 | 2025 | Phasix Mesh |
| Endo Pharmaceuticals INC. | $118.19 | 2021 | |
| Depuy Synthes Sales INC. | $39.23 | 2023 | Cementralizer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Salih Colakoglu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.